President Donald Trump has placed prescription drug affordability at the center of his agenda ahead of the upcoming midterm elections, promising sweeping reductions that he described as a “shock to the system.” Framing the initiative as long overdue relief for millions of Americans, Trump said lowering medication costs has been a consistent goal and remains one of his administration’s top priorities as voters continue to feel pressure from rising healthcare expenses.

A key element of the plan involves a new agreement with Pfizer, which Trump said will allow state Medicaid programs to purchase certain medications at “most-favored-nation” prices. Under this model, U.S. programs would pay rates comparable to the lowest prices offered in other developed countries. Examples shared include significant reductions across several widely used treatments, with some drugs seeing cuts ranging from roughly 40 percent to as much as 80 percent.

According to the President, this deal represents only the first step in a broader strategy aimed at reshaping how prescription drugs are priced nationwide. Trump indicated that at least one additional major pharmaceutical company is expected to announce similar pricing agreements in the near future. He positioned the effort as a way to address what he called long-standing global pricing imbalances, arguing that Americans have historically paid more while other countries benefited from lower costs.

Trump also tied the initiative directly to everyday household concerns, noting that lower prescription prices could ease financial strain for families managing chronic conditions or ongoing treatments. As the midterm elections approach, he emphasized that the policy is designed to deliver visible, measurable savings while still allowing pharmaceutical companies to operate profitably. The administration’s message is clear: drug affordability is not just a policy issue, but a pocketbook one that could shape how voters view healthcare leadership in the months ahead.